Hello and welcome to the details of Japan approves Gilead Science’s remdesivir as Covid-19 drug and now with the details
TOKYO, May 7 — Japan has approved Gilead Sciences Inc’s remdesivir as a treatment for COVID-19, the health ministry said on Thursday, making it the country’s first officially authorized drug for the coronavirus disease.
Japan reached the decision just three days after the U.S. drug maker filed for fast-track approval for the treatment.
Remdesivir will be given to patients with severe Covid-19 symptoms, a Japanese health ministry official said at a press briefing. With no other approved treatments for Covid-19, interest in the drug is growing around the world.
Remdesivir was granted authorisation last week by the US Food and Drug Administration for emergency use for the disease caused by the coronavirus.
Japan, with just over 16,000 infections and under 800 deaths, has recorded has fewer cases than other major industrialised nations.
However, a steady rise in cases has put pressure on medical facilities in some parts of the country, and drug that helps patients recover more quickly could help in freeing up hospital beds.
On Monday, Japanese Prime Minister Shinzo Abe extended a month-long state of emergency until the end of May in a bid to slow the spread of the coronavirus.
Gilead on Tuesday said it was in discussion with several companies, including generic drug makers in India and Pakistan to produce remdesivir in large quantities. — Reuters
These were the details of the news Japan approves Gilead Science’s remdesivir as Covid-19 drug for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
